Although other medication may thus not be affected by individual variance in CYP2D6 metabolization, this enzyme remains the strongest candidate for PGx-guided treatment for psychopharmaceutics and psychosis medication (van Westrhenen et al., 2021). The gene discussed is CYP2D6; the disease is psychotic disorder.